MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 162.7 USD | -0.36% |
|
+23.53% | +64.81% |
| 06:32pm | Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... |  |
| 03:28pm | The market is good to go until Nvidia’s next quarterly results | |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 17 M€ | +5.12% | - | |
| 0.20% | 330 M€ | -.--% | ||
| 0.19% | 6 M€ | +17.98% | - | |
| 0.18% | 121 M€ | +8.39% | - | |
| 0.17% | 1 M€ | -.--% | - | |
| 0.17% | 744 M€ | +10.58% | ||
| 0.17% | 8 M€ | +7.53% | - | |
| 0.16% | 26 M€ | +23.46% | - | |
| 0.16% | 9 M€ | +10.39% | ||
| 0.15% | 50 M€ | +11.38% | ||
| 0.15% | 2,517 M€ | +13.67% | - | |
| 0.14% | 559 M€ | +14.30% | ||
| 0.14% | 1,848 M€ | +18.39% | - | |
| 0.13% | 35 M€ | +9.77% | - | |
| 0.12% | 57 M€ | +23.43% | - | |
| 0.11% | 655 M€ | -.--% | - | |
| 0.11% | 273 M€ | -.--% | ||
| 0.11% | 1,174 M€ | +23.54% | ||
| 0.11% | 9 M€ | +10.49% | - | |
| 0.11% | 1 M€ | -.--% | ||
| 0.10% | 283 M€ | +22.07% | ||
| 0.09% | 34 M€ | +13.78% | - | |
| 0.09% | 104 M€ | +10.52% | ||
| 0.09% | 115 M€ | +4.22% | - |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
31/05/2024
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +64.81% | 62.59B | |
| -1.38% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.30% | 26.21B | |
| -21.69% | 19.09B | |
| +4.95% | 13.08B | |
| +25.46% | 12.26B | |
| +28.44% | 12.05B | |
| -7.94% | 11.28B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.
